Journal Article
. 2012 Sep;72(9).
doi: 10.1055/s-0032-1315340.

Biomarkers in Breast Cancer - An Update

M Schmidt 1 P A Fasching 2 M W Beckmann 2 H Kölbl 1 
Affiliations
  • PMID: 26640290
  •     73 References
  •     19 citations

Abstract

The therapy of choice for breast cancer patients requiring adjuvant chemo- or radiotherapy is increasingly guided by the principle of weighing the individual effectiveness of the therapy against the associated side effects. This has only been made possible by the discovery and validation of modern biomarkers. In the last decades and in the last few years some biomarkers have been integrated in clinical practice and a number have been included in modern study concepts. The importance of biomarkers lies not merely in their prognostic value indicating the future course of disease but also in their use to predict patient response to therapy. Due to the many subgroups, mathematical models and computer-assisted analysis are increasingly being used to assess the prognostic information obtained from established clinical and histopathological factors. In addition to describing some recent computer programmes this overview will focus on established molecular markers which have already been extensively validated in clinical practice and on new molecular markers identified by genome-wide studies.

Keywords: Her2/neu (human epidermal growth factor receptor); biomarker; breast cancer.

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Ann S Knoop, Helle Knudsen, +9 authors, Danish Breast Cancer Cooperative Group.
J Clin Oncol, 2005 Oct 20; 23(30). PMID: 16234514
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.
Gordon C Wishart, Elizabeth M Azzato, +5 authors, Paul D P Pharoah.
Breast Cancer Res, 2010 Jan 08; 12(1). PMID: 20053270    Free PMC article.
Gene expression profiling in breast cancer: classification, prognostication, and prediction.
Jorge S Reis-Filho, Lajos Pusztai.
Lancet, 2011 Nov 22; 378(9805). PMID: 22098854
Highly Cited. Review.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
D F Hayes, R C Bast, +10 authors, R J Winn.
J Natl Cancer Inst, 1996 Oct 16; 88(20). PMID: 8841020
Highly Cited. Review.
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.
Alan Mackay, Britta Weigelt, +7 authors, Jorge S Reis-Filho.
J Natl Cancer Inst, 2011 Mar 23; 103(8). PMID: 21421860    Free PMC article.
Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
John M S Bartlett, Alison Munro, +3 authors, Chris J Twelves.
J Clin Oncol, 2008 Sep 05; 26(31). PMID: 18768436
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
The humoral immune system has a key prognostic impact in node-negative breast cancer.
Marcus Schmidt, Daniel Böhm, +7 authors, Mathias Gehrmann.
Cancer Res, 2008 Jul 03; 68(13). PMID: 18593943
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.
Christoph Thomssen, Nadia Harbeck, +7 authors, Martina Vetter.
J Natl Cancer Inst, 2009 Jun 19; 101(14). PMID: 19535782
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
G C Wishart, C D Bajdik, +34 authors, P D P Pharoah.
Br J Cancer, 2012 Aug 02; 107(5). PMID: 22850554    Free PMC article.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, +3 authors, W L McGuire.
Science, 1987 Jan 09; 235(4785). PMID: 3798106
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
T Petit, M Wilt, +7 authors, J-P Ghnassia.
Eur J Cancer, 2004 Jan 20; 40(2). PMID: 14728934
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates.
Gabriela Alexe, Gul S Dalgin, +9 authors, Gyan Bhanot.
Cancer Res, 2007 Nov 17; 67(22). PMID: 18006808
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
Andrew E Teschendorff, Ahmad Miremadi, +2 authors, Carlos Caldas.
Genome Biol, 2007 Aug 09; 8(8). PMID: 17683518    Free PMC article.
Highly Cited.
Subtypes of breast cancer show preferential site of relapse.
Marcel Smid, Yixin Wang, +5 authors, John W M Martens.
Cancer Res, 2008 May 03; 68(9). PMID: 18451135
Highly Cited.
Use of archived specimens in evaluation of prognostic and predictive biomarkers.
Richard M Simon, Soonmyung Paik, Daniel F Hayes.
J Natl Cancer Inst, 2009 Oct 10; 101(21). PMID: 19815849    Free PMC article.
Highly Cited.
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, +19 authors, International Ki-67 in Breast Cancer Working Group.
J Natl Cancer Inst, 2011 Oct 01; 103(22). PMID: 21960707    Free PMC article.
Highly Cited.
First--select the target: better choice of adjuvant treatments for breast cancer patients.
A Goldhirsch, A S Coates, +4 authors, St Gallen Expert Panel Members.
Ann Oncol, 2006 Oct 31; 17(12). PMID: 17071934
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Invasive Breast Cancer: Recognition of Molecular Subtypes.
Johanna D Strehl, David L Wachter, +2 authors, Arndt Hartmann.
Breast Care (Basel), 2011 Dec 03; 6(4). PMID: 22135623    Free PMC article.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Insight into the heterogeneity of breast cancer through next-generation sequencing.
Hege G Russnes, Nicholas Navin, James Hicks, Anne-Lise Borresen-Dale.
J Clin Invest, 2011 Oct 04; 121(10). PMID: 21965338    Free PMC article.
Highly Cited. Review.
Concordance among gene-expression-based predictors for breast cancer.
Cheng Fan, Daniel S Oh, +5 authors, Charles M Perou.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899776
Highly Cited.
UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.
R Peto, J Boreham, +2 authors, V Beral.
Lancet, 2000 Jun 01; 355(9217). PMID: 10832853
Highly Cited.
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
Shaheenah Dawood, Kristine Broglio, +2 authors, Sharon H Giordano.
J Clin Oncol, 2009 Nov 26; 28(1). PMID: 19933921    Free PMC article.
Highly Cited.
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Giuseppe Viale, Meredith M Regan, +16 authors, International Breast Cancer Study Group.
J Natl Cancer Inst, 2008 Jan 31; 100(3). PMID: 18230798
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
Stella Mook, Marjanka K Schmidt, +6 authors, Peter M Ravdin.
Lancet Oncol, 2009 Oct 06; 10(11). PMID: 19801202
Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
So-Youn Jung, Wonshik Han, +11 authors, Dong-Young Noh.
Ann Surg Oncol, 2009 Feb 17; 16(5). PMID: 19219507
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Jeffrey S Ross, Elzbieta A Slodkowska, +3 authors, Gabriel N Hortobagyi.
Oncologist, 2009 Apr 07; 14(4). PMID: 19346299
Highly Cited. Review.
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.
M Schmidt, A Victor, +12 authors, C Thomssen.
Ann Oncol, 2008 Oct 01; 20(2). PMID: 18824499
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Effect of screening and adjuvant therapy on mortality from breast cancer.
Donald A Berry, Kathleen A Cronin, +8 authors, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.
N Engl J Med, 2005 Oct 28; 353(17). PMID: 16251534
Highly Cited.
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
Michele De Laurentiis, Grazia Arpino, +13 authors, Sabino De Placido.
Clin Cancer Res, 2005 Jul 08; 11(13). PMID: 16000569
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.
Marcus Schmidt, Birte Hellwig, +33 authors, Jan G Hengstler.
Clin Cancer Res, 2012 Feb 22; 18(9). PMID: 22351685
Highly Cited.
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Achim Rody, Uwe Holtrich, +10 authors, Manfred Kaufmann.
Breast Cancer Res, 2009 Mar 11; 11(2). PMID: 19272155    Free PMC article.
Highly Cited.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P Look, Wim L J van Putten, +37 authors, John A Foekens.
J Natl Cancer Inst, 2002 Jan 17; 94(2). PMID: 11792750
Highly Cited.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Marco Colleoni, Giuseppe Viale, +13 authors, Aron Goldhirsch.
Clin Cancer Res, 2004 Oct 12; 10(19). PMID: 15475452
HER2 and response to paclitaxel in node-positive breast cancer.
Daniel F Hayes, Ann D Thor, +14 authors, Cancer and Leukemia Group B (CALGB) Investigators.
N Engl J Med, 2007 Oct 12; 357(15). PMID: 17928597
Highly Cited.
A three-gene model to robustly identify breast cancer molecular subtypes.
Benjamin Haibe-Kains, Christine Desmedt, +4 authors, Christos Sotiriou.
J Natl Cancer Inst, 2012 Jan 21; 104(4). PMID: 22262870    Free PMC article.
Highly Cited.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Jan C Brase, Marcus Schmidt, +7 authors, Mathias C Gehrmann.
Clin Cancer Res, 2010 Apr 08; 16(8). PMID: 20371687
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Reporting recommendations for tumor marker prognostic studies.
Lisa M McShane, Douglas G Altman, +4 authors, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
J Clin Oncol, 2005 Sep 21; 23(36). PMID: 16172462
Highly Cited.
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
F Jänicke, M Schmitt, +4 authors, H Graeff.
Breast Cancer Res Treat, 1993 Jan 01; 24(3). PMID: 8435475
Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett.
J Clin Oncol, 2005 Sep 30; 23(28). PMID: 16192605
Highly Cited. Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, +13 authors, Lajos Pusztai.
Clin Cancer Res, 2005 Aug 24; 11(16). PMID: 16115903
Highly Cited.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Clinical application of the 70-gene profile: the MINDACT trial.
Fatima Cardoso, Laura Van't Veer, +3 authors, Martine J Piccart-Gebhart.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258980
Highly Cited.
Coordinates in the universe of node-negative breast cancer revisited.
Marcus Schmidt, Jan G Hengstler, +2 authors, Mathias C Gehrmann.
Cancer Res, 2009 Mar 26; 69(7). PMID: 19318558
Review.
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
Peter A Fasching, Katharina Heusinger, +14 authors, David L Wachter.
BMC Cancer, 2011 Nov 16; 11. PMID: 22081974    Free PMC article.
Highly Cited.
A population-based validation of the prognostic model PREDICT for early breast cancer.
G C Wishart, C D Bajdik, +5 authors, P D P Pharoah.
Eur J Surg Oncol, 2011 Mar 05; 37(5). PMID: 21371853
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Giuseppe Viale, Anita Giobbie-Hurder, +18 authors, Breast International Group Trial 1-98.
J Clin Oncol, 2008 Nov 05; 26(34). PMID: 18981464    Free PMC article.
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
Elissa M Ozanne, Dejana Braithwaite, +3 authors, Jeffrey Belkora.
J Clin Oncol, 2008 Dec 03; 27(2). PMID: 19047286
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
John M S Bartlett, Alison F Munro, +13 authors, Christopher J Poole.
Lancet Oncol, 2010 Jan 19; 11(3). PMID: 20079691
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Kathleen I Pritchard, Lois E Shepherd, +5 authors, National Cancer Institute of Canada Clinical Trials Group.
N Engl J Med, 2006 May 19; 354(20). PMID: 16707747
Highly Cited.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
F Jänicke, A Prechtl, +8 authors, German N0 Study Group.
J Natl Cancer Inst, 2001 Jun 21; 93(12). PMID: 11416112
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
J Chang, T J Powles, +5 authors, M Dowsett.
Clin Cancer Res, 2000 Feb 26; 6(2). PMID: 10690547
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.
E C Inwald, M Klinkhammer-Schalke, +4 authors, O Ortmann.
Breast Cancer Res Treat, 2013 May 16; 139(2). PMID: 23674192    Free PMC article.
Highly Cited.
[Future of mammography-based imaging].
R Schulz-Wendtland, T Wittenberg, +9 authors, P A Fasching.
Radiologe, 2014 Feb 27; 54(3). PMID: 24570108
Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma.
David L Wachter, Arndt Hartmann, +4 authors, Abbas Agaimy.
Biomed Res Int, 2014 Apr 05; 2014. PMID: 24701575    Free PMC article.
Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer.
U Andergassen, N S Kasprowicz, +10 authors, for the SUCCESS study group.
Geburtshilfe Frauenheilkd, 2013 Jan 01; 73(1). PMID: 24771886    Free PMC article.
Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.
P A Fasching, A B Ekici, +14 authors, M W Beckmann.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(12). PMID: 24771903    Free PMC article.
Epidemiology of Breast Cancer - Current Figures and Trends.
N Eisemann, A Waldmann, A Katalinic.
Geburtshilfe Frauenheilkd, 2013 Feb 01; 73(2). PMID: 24771909    Free PMC article.
Assessment of University Gynaecology Clinics Based on Quality Reports.
E F Solomayer, A Rody, D Wallwiener, M W Beckmann.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(7). PMID: 24771927    Free PMC article.
Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry.
E C Inwald, O Ortmann, +4 authors, M Klinkhammer-Schalke.
Biomed Res Int, 2014 Apr 30; 2014. PMID: 24779005    Free PMC article.
Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?
Juhasz-Böss Ingolf, Mavrova Russalina, +6 authors, Herr Daniel.
Biomed Res Int, 2014 May 02; 2014. PMID: 24783217    Free PMC article.
Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.
B A S Jaeger, J Jueckstock, +11 authors, B Rack.
Biomed Res Int, 2014 May 07; 2014. PMID: 24800234    Free PMC article.
Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
Markus Wallwiener, Sabine Riethdorf, +15 authors, Andreas Schneeweiss.
BMC Cancer, 2014 Jul 13; 14. PMID: 25015676    Free PMC article.
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.
P A Fasching, S Y Brucker, +14 authors, A Schneeweiss.
Geburtshilfe Frauenheilkd, 2015 Feb 17; 75(1). PMID: 25684786    Free PMC article.
Breast Cancer Update 2014 - Focus on the Patient and the Tumour.
N Maass, F Schütz, +7 authors, M P Lux.
Geburtshilfe Frauenheilkd, 2015 Mar 24; 75(2). PMID: 25797960    Free PMC article.
Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.
M Banys-Paluchowski, H Schneck, +7 authors, H Neubauer.
Geburtshilfe Frauenheilkd, 2015 Apr 29; 75(3). PMID: 25914415    Free PMC article.
Advances in Breast Cancer - Looking Back over the Year.
D Lüftner, M P Lux, +7 authors, H-C Kolberg.
Geburtshilfe Frauenheilkd, 2012 Dec 01; 72(12). PMID: 26640285    Free PMC article.
Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.
Florin-Andrei Taran, Andreas Schneeweiss, +19 authors, Florian Schütz.
Geburtshilfe Frauenheilkd, 2018 Mar 27; 78(3). PMID: 29576629    Free PMC article.
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.
Paul Gass, Michael Untch, +18 authors, Naiba Nabieva.
Geburtshilfe Frauenheilkd, 2018 Jul 31; 78(7). PMID: 30057427    Free PMC article.
Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.
Achim Wöckel, Michael P Lux, +17 authors, Hans-Christian Kolberg.
Geburtshilfe Frauenheilkd, 2018 Dec 01; 78(11). PMID: 30498278    Free PMC article.
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
Wolfgang Janni, Andreas Schneeweiss, +14 authors, Johannes Ettl.
Geburtshilfe Frauenheilkd, 2019 Mar 19; 79(3). PMID: 30880825    Free PMC article.